Evidence base — read this first
Part of a family of short synthetic peptides (2-4 amino acids) developed by Vladimir Khavinson's research group, each targeted at a specific tissue/organ. The evidence base for this entire peptide family shares the same limitation: it's concentrated almost entirely within this one research lineage (largely the same institute, often the same handful of authors), is mostly preclinical (rodent, cell-culture) or small Russian human pilot work, and hasn't been independently replicated by unaffiliated Western labs in a way this research pass could verify. None of these compounds is FDA or EMA approved for human use anywhere.
Benefits
Livagen (Lys-Glu-Asp-Ala) is pitched as a liver-tissue peptide for hepatic function/detoxification support within the same research program. No independently-verified specific study was confirmed for this compound in this research pass.
What does this actually target?+
Liver tissue specifically — a hepatic bioregulator from the same Khavinson research family, designed to support liver cell gene-regulation and function using the same short-peptide mechanism as Cardiogen, Cartalax, and the others.
Looking for something specific, or placing a wholesale order? Send us a DM or email.